3D Contrast Enhanced UltraSound in perfusion studies of early renal transplants

3D Contrast Enhanced UltraSound in perfusion studies of early renal transplants: a non-randomised study

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN44785771

Enrollment

105

Registered

2012-06-29

Start date

2011-03-04

Completion date

Unknown

Last updated

2018-03-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Topic: Renal and Urogenital

Interventions

Contrast enhanced ultrasound: Single examination using a 2.4mls injection of Sonovue contrast media.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. All renal transplant patients that undergo surgery within the collection period for the study until study population is acheived (N=105) 2. Male & Female ; Lower Age Limit 18 years

Exclusion criteria

Exclusion criteria: 1. Any patient under 18 years of age 2. A pregnant patient and 3. Any patient excluded due to contraindications as listed in the manufacturers guidelines for the contrast media used

Design outcomes

Primary

Measure	Time frame
Perfusion defect rates using 99mTc-diethylenetriamine pentaacetic acid (DTPA) renogram	—

Secondary

Measure	Time frame
Graft viability up to 3 months post-op measured by serum results and histology reports.	—

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026